Last updated: February 27, 2026
What is the drug associated with NDC 68382-0998?
NDC 68382-0998 refers to Xywav (calcium, magnesium, potassium, and sodium oxybates), approved by the FDA in July 2020. It is indicated for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy and for idiopathic hypersomnia.
Market Overview
Market Size and Trends
- The narcolepsy treatment market was valued at approximately USD 340 million in 2022.
- Xywav's market share is estimated at 30-40%, following its approval, primarily replacing branded sodium oxybate (Xyrem).
- The overall market is driven by the increasing diagnosis of narcolepsy and the limited treatment options.
Competitive Landscape
- Xyrem (sodium oxybate): The predecessor drug, marketed by Jazz Pharmaceuticals, holds a significant portion of the narcolepsy treatment market.
- Elsewhere: Stimulants like modafinil (Provigil), armodafinil (Nuvigil), and sodium oxybate products compete on symptom management but lack FDA approval for narcolepsy.
Key Players
| Company |
Product |
Market Share (Est.) |
Notes |
| Jazz Pharmaceuticals |
Xyrem |
60-70% |
Established leader; high prescribing rate |
| Marinus Pharmaceuticals |
Xywav |
30-40% |
Introduced in 2020; reduced Xyrem use |
Pricing Analysis
Current Pricing Structure
- Xywav (NDC 68382-0998): Wholesale acquisition cost (WAC) is approximately USD 35,500 per 30-day supply (reference 2023 data).
- Xyrem: WAC roughly USD 27,500 per 30-day supply, but actual patient prices tend to be higher after insurance, pharmacy benefit manager discounts, and rebates.
Price Trends
- Xywav's price is approximately 30% higher than Xyrem, reflecting its formulation and potential benefits.
- Insurance coverage often favors Xywav due to its improved safety profile, influencing market share and pricing.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range (per 30-day supply) |
Assumptions |
| 2024 |
USD 36,000 – USD 38,000 |
Moderate inflation, market stability |
| 2025 |
USD 36,500 – USD 39,000 |
Slight market expansion |
| 2026 |
USD 37,000 – USD 40,000 |
Increased adoption, generic entry unlikely before 2030 |
| 2027 |
USD 37,500 – USD 41,000 |
Insurance adjustments, price plateau |
| 2028 |
USD 38,000 – USD 42,000 |
Continued demand, potential new formulations |
Market Drivers for Price Changes
- Demand growth: Rising narcolepsy diagnoses and increased physician awareness.
- Regulatory environment: No near-term plans for generic entry, supporting stable pricing.
- Reimbursement policies: Coverage policies favor Xywav integration, maintaining high prices.
- Introduction of competitor products: Limited in the short term, supporting price stability.
Regulatory and Patent Landscape
- Patents: Xywav benefits from patent protections that extend until at least 2030.
- Market exclusivity: US patent protections and exclusivity support pricing power.
- Regulatory updates: No significant regulatory hurdles anticipated that would impact pricing before 2025.
Key Takeaways
- NDC 68382-0998 (Xywav) entered a niche market with high unmet needs.
- The current price is around USD 35,500 per 30-day supply, with an upward trend forecasted for the next five years.
- Market share favors the newer formulation due to safety and efficacy benefits and high switching rates from Xyrem.
- Patent protections and market exclusivity underpin pricing stability in the near term.
- Competition from generics is unlikely before 2030, supporting sustained premium pricing.
FAQs
What factors could impact future pricing of Xywav?
Reimbursement policy changes, patent challenges, or introduction of generic versions could lower prices. Market competition and demand fluctuations also influence pricing strategies.
How does Xywav compare to Xyrem in terms of market share?
Xywav captures an estimated 30-40% of the oxybate market, mainly replacing Xyrem due to safety benefits.
What is the potential for generic competition?
Patent protections extend until at least 2030, delaying generic entry and preserving high prices.
Are payers likely to favor Xywav over Xyrem?
Yes, due to safety profile improvements, leading to better coverage and formulary positioning.
What is the long-term market outlook?
Demand for narcolepsy treatments is expected to rise, supporting steady revenues. Patent protections and limited competition suggest pricing will remain stable through 2028.
References
- Food and Drug Administration. (2020). FDA approves Xywav for narcolepsy.
- IQVIA. (2023). U.S. Prescription Market Data.
- Jazz Pharmaceuticals. (2023). Xyrem and Xywav pricing and formulary statuses.
- MarketWatch. (2023). Narcolepsy drugs market forecast.
- U.S. Patent and Trademark Office. (2022). Patent status of oxybate formulations.
